A major contribution to ocular morbidity is lacrimal dysfunction, affecting over 10 million Americans, primarily women. At least two to four million cases are autoimmune-mediated and accompanied by additional symptoms, which lead to the diagnosis of Sjogren's syndrome. Development of primary lacrimal deficiency and Sjogren's syndrome are associated with changes in hormonal status and also environmental and genetic factors. Although the precise mechanisms involved in disease development remain unclear, these diseases are associated with impaired release of secretory products into ocular surface fluid by the lacrimal gland. The principal cell of the lacrimal gland and primary contributor of proteins into ocular fluid is the lacrimal acinar cell. Disease-related changes in release of secretory products into ocular fluid imply, at some level, changes in the molecular mechanisms responsible for exocytosis at the apical plasma membrane of lacrimal acini. Our approach to the study of diseases affecting lacrimal gland secretory functions has therefore focused on elucidating the mechanisms responsible for accurate exocytotic release of secretory pro- ducts at the apical plasma membrane of healthy lacrimal acini, and to determine how changes in these mechanisms are related to the establishment and progression of lacrimal disease. Findings during the previous project period have defined the involvement of several key effectors of exocytosis including rab3D, vesicle-associated membrane protein 2, cytoplasmic dynein and actin filaments. Moreover, compensatory retrieval of acinar apical plasma membrane, essential for regeneration of secretory vesicles, utilizes a unique clathrin-mediated endocytotic mechanism involving actin, syndapins and N-WASP. Key questions regarding other fundamental mechanisms of lacrimal acinar exocytotic pathways remain unanswered, and will be addressed in Aims #1 and #2 using reconstituted primary rabbit lacrimal acini as an experimental model. To begin to address the changes in exocytotic pathways associated with initiation and progression of Sjogren's syndrome, Aim #3 probes age- and sex-related changes in organization and composition of the exocytotic pathway in lacrimal glands from control BALB/c mice as well as NOD mice, an experimental model of Sjogren's syndrome. Technically, these aims utilize an array of techniques including light and electron microscopy, biochemical analysis of subcellular membranes and proteomics.
The specific aims are:
Aim #1. Do lacrimal acinar cells contain distinct secretory vesicle populations? Aim #2. How do actin filaments facilitate exocytosis of secretory vesicles in lacrimal acinar cells? Aim #3. What components of the exocytotic pathway undergo age-related changes in lacrimal glands from BALB/c and NOD mice?

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY011386-11
Application #
7210566
Study Section
Special Emphasis Panel (ZRG1-AED (01))
Program Officer
Shen, Grace L
Project Start
1996-07-01
Project End
2009-03-31
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
11
Fiscal Year
2007
Total Cost
$356,126
Indirect Cost
Name
University of Southern California
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Ju, Yaping; Janga, Srikanth Reddy; Klinngam, Wannita et al. (2018) NOD and NOR mice exhibit comparable development of lacrimal gland secretory dysfunction but NOD mice have more severe autoimmune dacryoadenitis. Exp Eye Res 176:243-251
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Klinngam, Wannita; Fu, Runzhong; Janga, Srikanth R et al. (2018) Cathepsin S Alters the Expression of Pro-Inflammatory Cytokines and MMP-9, Partially through Protease-Activated Receptor-2, in Human Corneal Epithelial Cells. Int J Mol Sci 19:
Janga, Srikanth R; Shah, Mihir; Ju, Yaping et al. (2018) Longitudinal analysis of tear cathepsin S activity levels in male non-obese diabetic mice suggests its potential as an early stage biomarker of Sjögren's Syndrome. Biomarkers :1-12
Edman, Maria C; Janga, Srikanth R; Meng, Zhen et al. (2018) Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren's Syndrome patients. Sci Rep 8:11044
Hawley, Dillon; Tang, Xin; Zyrianova, Tatiana et al. (2018) Myoepithelial cell-driven acini contraction in response to oxytocin receptor stimulation is impaired in lacrimal glands of Sjögren's syndrome animal models. Sci Rep 8:9919
Meng, Zhen; Klinngam, Wannita; Edman, Maria C et al. (2017) Interferon-? treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren's Syndrome. PLoS One 12:e0184781
Aluri, Hema S; Samizadeh, Mahta; Edman, Maria C et al. (2017) Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Tear Production in a Mouse Model of Sjögren's Syndrome. Stem Cells Int 2017:3134543
Shah, Mihir; Edman, Maria C; Reddy Janga, Srikanth et al. (2017) Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome. Invest Ophthalmol Vis Sci 58:372-385
Meng, Zhen; Edman, Maria C; Hsueh, Pang-Yu et al. (2016) Imbalanced Rab3D versus Rab27 increases cathepsin S secretion from lacrimal acini in a mouse model of Sjögren's Syndrome. Am J Physiol Cell Physiol 310:C942-54

Showing the most recent 10 out of 75 publications